Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases

  • Ameri, Ahmad (Department of Clinical Oncology, Shahid Beheshti University of Medical Sciences) ;
  • Mortazavi, Nafiseh (Department of Pathology, Shahid Beheshti University of Medical Sciences) ;
  • Ahmadi, Helaleh Khoshbakht (Department of Clinical Oncology, Shahid Beheshti University of Medical Sciences) ;
  • Novin, Kambiz (Department of Clinical Oncology, Shahid Beheshti University of Medical Sciences)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

To investigate whether excision repair cross complementing-group1 (ERCC1) expression status could serve as a bio-predictor of response to platinum-based induction chemotherapy for head and neck cancers (HNCs) patients with a diagnosis of epithelial HNC were studied retrospectively. Paraffin embedded tumor samples of the patients were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) to determine ERCC1 expression status and its correlation with response to platinum-based induction chemotherapy was investigated. Of 44 included patients, 33 were male (75%) and 11 were female (25%) with a mean age of 53 years. Some 36% of patients whose tumor samples had high ERCC1 expression showed no response to induction chemotherapy. The value for patients with low ERCC1 expression was 9% and the difference was statistically significant (p=0.03). The ERCC1 expression state did not significantly vary between patient groups according to sex, age, primary tumor site, and tumor and node stage. Our study indicates that ERCC1 expression status detected by RT-PCR might serve as a bio-predictor of response to platinum-based induction chemotherapy for epithelial HNCs.

Keywords

References

  1. Alvarenga LM, Ruiz MT, Pavarino-Bertelli EC, et al (2008). Epidemiologic evaluation of head and neck patients in a university hospital of Northwestern Sao Paulo State. Braz J Otorhinolaryngol, 74, 68-73. https://doi.org/10.1016/S1808-8694(15)30753-9
  2. Argiris A (2005). Induction chemotherapy for head and neck cancer: will history repeat itself. J Natl Compr Canc Netw, 3, 393-403. https://doi.org/10.6004/jnccn.2005.0020
  3. Bauman JE, Austin MC, Schmidt R, et al (2013). ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer, 109, 2096-105. https://doi.org/10.1038/bjc.2013.576
  4. Bohanes P, Labonte MJ, Lenz HJ (2011). A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer, 10, 157-64. https://doi.org/10.1016/j.clcc.2011.03.024
  5. Brockstein B, Haraf DJ, Rademaker AW, et al (2004). Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol, 15, 1179-86. https://doi.org/10.1093/annonc/mdh308
  6. Carey TE, Prince MEP (2015). Molecular Biology of Head and Neck Cancers. In 'Cancer principle and practice of oncology', Devita VT, Hellman S, Rosenberg SA. 10th ed. Wolters Kluwer, Philadelphia , 416-21.
  7. Chen S, Zhang J, Wang R, Luo X, Chen H (2010). The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer, 70, 63-70. https://doi.org/10.1016/j.lungcan.2010.05.010
  8. Cohen EE, Karrison TG, Kocherginsky M, et al (2014). Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. Cancer Clin. Trials, 32, 2735-43.
  9. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  10. Fountzilas G, Bamias A, Kalogera-Fountzila A, et al (2009). Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res, 29, 529-38.
  11. Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al (2009). MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol, 2009, 305908.
  12. Gossage L, Madhusudan S (2007). Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev, 33, 565-77. https://doi.org/10.1016/j.ctrv.2007.07.001
  13. Handra-Luca A, Hernandez J, Mountzios G, et al (2007). Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res, 13, 3855-9. https://doi.org/10.1158/1078-0432.CCR-07-0252
  14. Hayes M, Lan C, Yan J, et al (2011). ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res, 31, 4135-9.
  15. Hitt R, Grau JJ, Lopez-Pousa A, et al (2013). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol, 25, 216-25.
  16. Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  17. Jun HJ, Ahn MJ, Kim HS, et al (2008). ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer, 99, 167-72. https://doi.org/10.1038/sj.bjc.6604464
  18. Koh Y, Kim TM, Jeon YK, et al (2009). Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol, 20, 1414-9. https://doi.org/10.1093/annonc/mdp002
  19. Langer CJ (2012). Exploring biomarkers in head and neck cancer. Cancer, 118, 3882-92. https://doi.org/10.1002/cncr.26718
  20. Li FY, Ren XB, Xie XY, Zhang J (2013). Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum-based chemotherapy in ovarian cancer. Asian Pac J Cancer Prev, 14, 7203-6. https://doi.org/10.7314/APJCP.2013.14.12.7203
  21. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method. Methods, 25, 402-8. https://doi.org/10.1006/meth.2001.1262
  22. Ragin CC, Modugno F, Gollin SM (2007). The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res, 86, 104-14. https://doi.org/10.1177/154405910708600202
  23. Vilmar A, Sorensen JB (2009). Excision repair cross complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer, 64, 131-9. https://doi.org/10.1016/j.lungcan.2008.08.006
  24. Zamble DB, Mu D, Reardon JT, et al (1996). Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry, 35, 10004-13. https://doi.org/10.1021/bi960453+
  25. Zhong LP, Zhang CP, Ren GX, et al (2012). Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol, 48, 1076-84.

Cited by

  1. Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review vol.10, pp.10, 2018, https://doi.org/10.3390/cancers10100376